(R)-carnitine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The subjects in the LC group had significantly lower level of MDA (1.8 ± 0.3 versus 2.0 ± 0.4 μmol/L, P = 0.01), higher levels of LC (40.0 ± 12.0 versus 35.2 ± 12.0 μmol/L, P = 0.02), and higher activities of CAT (13.1 ± 5.8 versus 10.6 ± 2.9 U/mg of protein, P < 0.01), SOD (20.7 ± 4.2 versus 13.1 ± 2.9 U/mg of protein, P < 0.01), and GPx (23.0 ± 3.1 versus 19.1 ± 2.3 U/mg of protein, P < 0.01) than those in the placebo group at week 12.”
Quoted verbatim from Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 mg/day L-carnitine as 500 mg twice daily for 12 weeks
- Population
- Male patients with coronary artery disease (at least 50% stenosis of a major coronary artery), 39 completers, week 12 values compared with starch placebo; single-blind
Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial.2014PMID:25092108Permalink
Keep reading
- Everything the graph holds on (R)-carnitine
- Every compound studied against Malondialdehyde (circulating)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5RXEHEA3M9D00GHWN15Q866